We Help You Understand
Treatment Decisions.
CancerCareE is not a hospital, not a medical provider. We are an independent platform that helps patients understand treatment options and—only at their explicit request—forwards their information to vetted institutions.
- ✦ $0 patient fees — We never charge patients
- ✦ Independent information on treatment pathways
- ✦ At your request, we introduce you to vetted institutions
- ✦ All medical decisions made by licensed physicians
Request Your Free Introduction
We forward only your name and contact information. No medical data is collected.
No fees. No obligation.
Legal Framework • Financial Transparency
Platform Transparency
Data from our network. Updated regularly.
Patients, Families & Physicians
We provide information and connection pathways to support informed decisions.
For Patients & Families
- Independent information on treatment options
- Connection to vetted institutions at your request
- Transparent cost information
- Multi-language support
For Advanced Cancer Cases
- Options when standard treatments are exhausted
- Introduction to centers offering CAR-T, TIL, NK, Gamma Delta
- Clinical trial matching information
For Referring Physicians
- Secure physician-to-physician portal
- Peer case review by specialist oncologists
- Clinical trial matching
- Anonymized outcome data
Meet Our Specialist Network
A growing network of independently vetted oncology specialists — every name here is real, every credential verified.
Dr. Bryan Liu
Dr. Qian Li
Mahzad
The Access Intelligence Framework
A rigorous, evidence-based approach to evaluating treatment pathways across three critical dimensions.
Clinical Viability
We analyze publicly available clinical data, peer-reviewed literature, and treatment guidelines to assess the scientific foundation of each pathway.
- Evidence-based therapy evaluation
- Clinical trial registry analysis
- Physician credential verification
Logistical Feasibility
We map the practical realities of cross-border care, from institutional accreditation to patient support infrastructure.
- International accreditation status (JCI, ISO)
- Language and cultural support
- Geographic accessibility analysis
Financial Transparency
We maintain absolute clarity on costs, fees, and our own revenue model—no hidden charges, no surprises.
- $0 patient facilitation fees
- Clear referral fee disclosure
- Direct hospital billing transparency
Global Oncology Access Trends
Data-driven insights from our introduction platform, reflecting real patient inquiry patterns.
Advanced Cellular & Immunotherapy
Evidence-based information on cutting-edge treatment options.
CAR-T Cell Therapy
Genetically modified T-cells targeting specific cancer antigens.
Lymphoma • Leukemia • Myeloma Learn about CAR-T →Gamma Delta T-Cell
Innate immune cells effective against solid tumors without HLA matching.
Solid Tumors • Lung • Liver Learn about Gamma Delta →TIL Therapy
Tumor-Infiltrating Lymphocytes expanded from the patient's own tumor.
Melanoma • Cervical • Ovarian Learn about TIL →NK Cell Therapy
Natural Killer cells providing innate immunity against cancer cells.
Blood Cancers • Solid Tumors Learn about NK cells →From Our Knowledge Base
Evidence-based guides drawn from our own published research and content library.
Understanding CAR-T Cell Therapy: Who Qualifies?
A plain-language breakdown of eligibility criteria.
Comparing Treatment Costs Across Countries
What actually drives the price difference between destinations.
Cancer Staging Systems, Explained Simply
How stage is determined and why it matters for treatment choice.
Is Advanced Cellular Therapy an Option?
An honest assessment framework based on clinical evidence.
✓ May Be Appropriate If
- Relapsed after 2+ standard treatments
- Specific cancer type (B-ALL, DLBCL, Myeloma)
- Adequate organ function
- Performance status ECOG 0-2
✕ May Not Be Suitable If
- Early-stage cancer
- Severe organ dysfunction
- Active autoimmune disease
- Performance status ECOG 3-4
? Requires Expert Review If
- Solid tumors (trial-dependent)
- Elderly patients (case-by-case)
- Prior CAR-T failure
- Rare cancer types
This is an informational guide, not medical advice.
Treatment Comparisons
Evidence-based comparisons to help you understand your options.
CAR-T vs Chemotherapy
Compare efficacy, side effects, and costs.
Read comparison →NK Cells vs CAR-T
Natural killer cells or modified T-cells.
Read comparison →China vs USA in Cellular Therapy
Cost, wait times, clinical trials, and quality of care.
Read comparison →TIL vs Immunotherapy
TIL compared with immune checkpoint inhibitors.
Read comparison →Research & Institutional Gateway
Collaborate with us to expand ethical, transparent patient access pathways.
For Hospitals & Clinics
Provide your clinical trial data and treatment pathways to our global patient network through our secure, compliance-first platform.
Learn More →For Universities & Researchers
Collaborate on cross-border oncology access research. Access our anonymized market intelligence and patient inquiry data.
Explore Collaboration →For Pharma & Biotech
Integrate your patient access programs with our intelligence platform. Reach qualified patients through ethical, transparent channels.
Partner With Us →From Our Founder
I started CancerCareE after seeing how often patients were pushed toward whichever provider paid the most — not whichever was right for them. Too many families are left navigating complex, life-or-death decisions without a trusted partner who has no conflict of interest. We're here to change that — one case at a time.
— Reza, Founder, CancerCareEFrequently Asked Questions
Common questions about our platform.